No Data
No Data
cspc pharma (01093) canceled 49.59 million shares already repurchased.
cspc pharma (01093) announced that the company has canceled 49.59 million shares repurchased on October 15, 2024...
Hong Kong Stocks Fall on Uncertainty in Further Stimulus; Pharma Firms Lead Decline
CSPC Pharma rose more than 6% in early trading. The group signed an exclusive licensing agreement with AstraZeneca.
CSPC Pharma (01093) rose 5.51% in early trading, now trading at 7.09 Hong Kong dollars, with a turnover of 0.585 billion Hong Kong dollars. CSPC Pharma has issued an announcement.
Intensive bullish news drives valuation repair, could CSPC Pharma (01093) turn bullish again with a new buying point?
The general upward trend may be coming to an end, and the subsequent on-site funds may pay more attention to the fundamentals and financial aspects of enterprises, with cspc pharma possibly remaining the target of fund chasing.
Goldman Sachs: Buy rating on CSPC Pharma (01093) with a target price of HK$10.03.
cspc pharma aims to complete 1-2 BD trades within 2024.
Announcement Highlights | new china life insurance: The net profit attributable to the mother is expected to increase by 95%-115% in the first three quarters; sunac: Sales in the first 9 months decreased by 48.68% year-on-year.
Wuxi Apptec: No decision has been made regarding the sale of its WuXi ATU business; Tencent: Spent 0.703 billion Hong Kong dollars to repurchase 1.56 million shares, repurchase price range is 438.6-474.8 Hong Kong dollars.